Vote Erika Smith
Erika R. Smith
City/Town where Organization Located
City/Town of Residence - this is for media placement
Company/organization description (<500 characters)
ReNetx Bio – a clinical stage company established to provide first-in-class therapeutics to treat damage to the central nervous system (CNS). The company's scientific founder, Dr. Stephen Strittmatter from Yale University, identified key factors that inhibit regrowth in the CNS. The company's novel protein therapeutic approach binds these inhibitors thereby enabling nerve fiber regrowth and increased synaptic plasticity for neural reconnection. ReNetX Bio has raised $25M, launched a Phase 1/2 clinical trial proof of concept trial and was granted "Fast Track Designation" from FDA.
Tell us about the entrepreneurial milestones you accomplished in 2019 (<500 characters) e.g., patents received, growth rate, and successful MVP, trial, or exit, etc…
Fast Track Designation from FDA, Launched Phase 1/2 Clinical Trial for Spinal Cord Injury, Entrepreneur of the Year - BioCT, Selected by New Haven Biz Innovation Awards 60 Ideas in 60 Minutes, Launched Executive Women in Bio (Diversity initiative)
What type of entrepreneur are you? Scaling Company: regional, national, or global business focus and greater than $1,000,000 in revenue in 2019; Scalable Venture: regional, national, or global business focus and less than $1,000,000 in revenue in 2019; Main Street: local business focus;Social Good: social enterprise or nonprofit focus
Student entrepreneur: Are you a student and younger than 25 as of December 31, 2019? YES or NO
What CT entrepreneur ecosystem resources (spaces, programs, events, schools, etc.) have helped you succeed? (<500 characters)
Connecticut Innovations, Yale, BioCT, New Haven Biz
What people are saying about Erika Smith ...
Erika Smith is the CEO of ReNetX Bio, a clinical stage, privately held company, located in New Haven, CT committed to developing breakthrough, first in class therapies to reverse damage in patients with neurological disease and injury. Over the last 25 years, she successfully advanced dozens of companies and technologies in life-sciences by leading the launch of three investment funds: the Blavatnik Fund for Innovation at Yale, the YEI (Yale) Innovation Fund, and the Center for Innovative Technology (CIT) BioLife Fund in partnership with Johnson Bill Kenney